A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants
PHASE1CompletedINTERVENTIONAL
Enrollment
6
Participants
Timeline
Start Date
February 28, 2014
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Conditions
Healthy Adult Females
Interventions
DRUG
Tenofovir
DRUG
Maraviroc
Trial Locations (1)
27599
CTRC University of North Carolina at Chapel Hill, Chapel Hill
All Listed Sponsors
lead
University of North Carolina, Chapel Hill
OTHER
NCT02039323 - A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants | Biotech Hunter | Biotech Hunter